Search
Search Results
##search.searchResults.foundPlural##
-
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1638PDF: 785HTML: 137 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2720PDF: 972HTML: 5494 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1186PDF: 799HTML: 256 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4633PDF: 1505HTML: 2225Untitled: 187Untitled: 202Untitled: 209Untitled: 191Untitled: 188 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3529PDF: 1357HTML: 166 -
THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
2139PDF: 915HTML: 6767Figure 1: 154 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2229PDF: 1537HTML: 571 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3163PDF: 1907HTML: 7450 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1752PDF: 687HTML: 2082Untitled: 186Untitled: 137Untitled: 151Untitled: 138Untitled: 144Untitled: 160Untitled: 167 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3232PDF: 1205HTML: 2170 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4689PDF: 1703HTML: 2685Untitled: 188 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1418PDF: 1112HTML: 169 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2396PDF: 1114HTML: 11770 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1292PDF: 1366PDF: 986HTML: 185 -
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
2999PDF: 1763HTML: 3535 -
AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS
2104PDF: 1153HTML: 3669 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2693PDF: 885HTML: 339Preferred Reviewers: 188 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
701PDF: 452HTML: 6243 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3614PDF: 1202HTML: 3861Untitled: 182Untitled: 240 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
888PDF: 323HTML: 76 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3292PDF: 1239HTML: 2187Fi.1 Gritti.Rambaldi: 182 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
3954PDF: 1856HTML: 1741 -
SOLITARY PLASMACYTOMA
3735PDF: 2124HTML: 1188fIGURES 1,2: 186 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3490PDF: 831HTML: 6693 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3365PDF: 1441HTML: 63 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1015PDF: 524HTML: 1670Figures: 140Fifures Sanz: 155tables Sanz: 163Untitled: 155







